Artera hits US first with pathology-based breast cancer risk tool’s clearance

ArteraAI Breast is designed to stratify breast cancer patients into high- and low-risk groups to guide treatment decisions. ArteraAI Breast is designed to stratify breast cancer patients into high- and low-risk groups to guide treatment decisions. HR+/HER2- is widely recognised as the most common breast cancer subtype. Credit: Tada Images / Shutterstock.com Artera has obtained US Food and Drug Administration (FDA) clearance for ArteraAI Breast, making it the first digital pathology–based risk stratification tool for breast cancer to receive clearance from the agency. ArteraAI Breast, a software tool that runs on Artera’s core multimodal artificial intelligence (MMAI) platform, applies AI…

Source: Medical Device Network